1. Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients. Issue 11 (17th May 2018) Authors: Dutzer, D.; Nasser, Y.; Berger, A. E.; Roblin, X.; Paul, S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 11(2018) Page Start: 1571 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Issue 5 (8th January 2018) Authors: Wils, P.; Bouhnik, Y.; Michetti, P.; Flourie, B.; Brixi, H.; Bourrier, A.; Allez, M.; Duclos, B.; Serrero, M.; Buisson, A.; Amiot, A.; Fumery, M.; Roblin, X.; Peyrin‐Biroulet, L.; Filippi, J.; Bouguen, G.; Abitbol, V.; Coffin, B.; Simon, M.; Laharie, D. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 5(2018) Page Start: 588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (2nd February 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease. Issue 7 (2nd September 2015) Authors: Paul, S.; Roblin, X.; Peyrin‐Biroulet, L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 42:Issue 7(2015) Page Start: 939 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease. (20th April 2015) Authors: Roblin, X.; Marotte, H.; Leclerc, M.; Del Tedesco, E.; Phelip, J.M.; Peyrin-Biroulet, L.; Paul, S. Journal: Journal of Crohn's and colitis Issue: Volume 9:Number 7(2015:Jul.) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The prevalence of right‐sided colonic diverticulosis and diverticular haemorrhage. (25th April 2013) Authors: Faucheron, J.‐L.; Roblin, X.; Bichard, P.; Heluwaert, F. Journal: Colorectal disease Issue: Volume 15:Number 5(2013) Page Start: e266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (March 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Issue 7 (31st January 2018) Authors: Yacoub, W.; Williet, N.; Pouillon, L.; Di‐Bernado, T.; De Carvalho Bittencourt, M.; Nancey, S.; Lopez, A.; Paul, S.; Zallot, C.; Roblin, X.; Peyrin‐Biroulet, L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 7(2018) Page Start: 906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort. Issue 4 (18th December 2017) Authors: Tadbiri, S.; Peyrin‐Biroulet, L.; Serrero, M.; Filippi, J.; Pariente, B.; Roblin, X.; Buisson, A.; Stefanescu, C.; Trang‐Poisson, C.; Altwegg, R.; Marteau, P.; Vaysse, T.; Bourrier, A.; Nancey, S.; Laharie, D.; Allez, M.; Savoye, G.; Gilletta, C.; Gagniere, C.; Vuitton, L. Other Names: Amiot Aurelien investigator.; Gagniere Charlotte investigator.; Serrero Melanie investigator.; Grimaud Jean‐Charles investigator.; Peyrin‐Biroulet Laurent investigator.; Zallot Camille investigator.; Bigard Marc‐Andre investigator.; Filippi Jerome investigator.; Hebuterne Xavier investigator.; Pa... Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 4(2018) Page Start: 485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Letter: thiopurines ‐ is less really more? Authors' reply. Issue 1 (11th December 2017) Authors: Roblin, X.; Paul, S.; Nancey, S.; Flourie, B. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 1(2018) Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗